Effects of atorvastatin treatment on left ventricular diastolic function in peritoneal dialysis patients—The ALEVENT clinical trial

Journal of Clinical Lipidology

Volumn 11, Issue 3, 2017, Pages 657-666

  Wu, Cho Kai ^a   Yeh, Chih Fan ^a   Chiang, Jiun Yang ^a   Lin, Ting Tse ^a   Wu, Yi Fan ^b   Chiang, Chih Kang ^b   Kao, Tze Wah ^a   Hung, Kuan Yu ^a   Huang, Jenq Wen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Atorvastatin; Inflammation; Left ventricular diastolic dysfunction; Peritoneal dialysis; Tissue Doppler imaging

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LIPID;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLOW RATE; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HEMODIALYSIS PATIENT; HUMAN; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TISSUE DOPPLER IMAGING; BLOOD; DIAGNOSTIC IMAGING; DIASTOLE; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECTS; DRUG THERAPY; HEART LEFT VENTRICLE FUNCTION; METABOLISM; MIDDLE AGED;

ATORVASTATIN CALCIUM; C-REACTIVE PROTEIN; DIASTOLE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85017131584     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2017.02.016     Document Type: Article

References (36)

1. 1 Bajraktari, G., Berbatovci-Ukimeraj, M., Hajdari, A., et al. Predictors of increased left ventricular filling pressure in dialysis patients with preserved left ventricular ejection fraction. Croat Med J 50:6 (2009), 543–549.
2. 2 Stenvinkel, P., Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton) 11:1 (2006), 36–41.
3. 3 Wu, C.K., Huang, Y.T., Lin, H.H., et al. Dissecting the mechanisms of left ventricular diastolic dysfunction and inflammation in peritoneal dialysis patients. PLoS One, 8(5), 2013, e62722.
4. 4 London, G.M., Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 16:2 (2003), 85–94.
5. 5 Cho, Y., Hawley, C.M., Johnson, D.W., Clinical causes of inflammation in peritoneal dialysis patients. Int J Nephrol, 2014, 2014, 909373.
6. 6 Wu, C.K., Lee, J.K., Chiang, F.T., et al. Plasma levels of tumor necrosis factor-alpha and interleukin-6 are associated with diastolic heart failure through downregulation of sarcoplasmic reticulum Ca2+ ATPase. Crit Care Med 39:5 (2011), 984–992.
7. 7 Wu, C.K., Lee, J.K., Wu, Y.F., et al. Left ventricular diastolic dysfunction in peritoneal dialysis: a forgotten risk factor. Medicine (Baltimore), 94(20), 2015, e819.
8. 8 Wanner, C., Krane, V., Marz, W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:3 (2005), 238–248.
9. 9 Fellstrom, B.C., Jardine, A.G., Schmieder, R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:14 (2009), 1395–1407.
10. 10 Ridker, P.M., Rifai, N., Pfeffer, M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98:9 (1998), 839–844.
11. 11 Lindahl, B., Toss, H., Siegbahn, A., et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 343:16 (2000), 1139–1147.
12. 12 Riesen, W.F., Engler, H., Risch, M., Korte, W., Noseda, G., Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 23:10 (2002), 794–799.
13. 13 van Wissen, S., Trip, M.D., Smilde, T.J., et al. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 165:2 (2002), 361–366.
14. 14 Liu, B., Zhang, J.Y., Cao, H.M., Wang, Q., Wang, H.B., Effect of rosuvastatin on ROCK activity, endothelial function, and inflammation in Asian patients with atherosclerosis. Intern Med 51:10 (2012), 1177–1182.
15. 15 Arnaud, C., Burger, F., Steffens, S., et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol 25:6 (2005), 1231–1236.
16. 16 Wu, C.K., Luo, J.L., Wu, X.M., et al. A propensity score-based case-control study of renin-angiotensin system gene polymorphisms and diastolic heart failure. Atherosclerosis 205:2 (2009), 497–502.
17. 17 Wu, C.K., Tsai, C.T., Chang, Y.C., et al. Genetic polymorphisms of the angiotensin II type 1 receptor gene and diastolic heart failure. J Hypertens 27:3 (2009), 502–507.
18. 18 Reisner, S.A., Lysyansky, P., Agmon, Y., Mutlak, D., Lessick, J., Friedman, Z., Global longitudinal strain: a novel index of left ventricular systolic function. J Am Soc Echocardiogr 17:6 (2004), 630–633.
19. 19 Ridker, P.M., Danielson, E., Fonseca, F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:21 (2008), 2195–2207.
20. 20 Kasner, M., Gaub, R., Sinning, D., et al. Global strain rate imaging for the estimation of diastolic function in HFNEF compared with pressure-volume loop analysis. Eur J Echocardiogr 11:9 (2010), 743–751.
21. 21 Palmer, S.C., Craig, J.C., Navaneethan, S.D., Tonelli, M., Pellegrini, F., Strippoli, G.F., Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 157:4 (2012), 263–275.
22. 22 Silbernagel, G., Fauler, G., Genser, B., et al. Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients. J Am Coll Cardiol 65:21 (2015), 2291–2298.
23. 23 Stenvinkel, P., Rodriguez-Ayala, E., Massy, Z.A., et al. Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. Clin J Am Soc Nephrol 1:2 (2006), 281–287.
24. 24 Kumar, S., Raftery, M., Yaqoob, M., Fan, S.L., Anti-inflammatory effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in peritoneal dialysis patients. Perit Dial Int 27:3 (2007), 283–287.
25. 25 Paraskevas, K.I., Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering. Int Urol Nephrol 40:1 (2008), 165–170.
26. 26 Prabhu, S.D., Cytokine-induced modulation of cardiac function. Circ Res 95:12 (2004), 1140–1153.
27. 27 Sciarretta, S., Paneni, F., Palano, F., et al. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin Sci (Lond) 116:6 (2009), 467–477.
28. 28 Ing, D.J., Zang, J., Dzau, V.J., Webster, K.A., Bishopric, N.H., Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. Circ Res 84:1 (1999), 21–33.
29. 29 Paulus, W.J., Tschope, C., Sanderson, J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28:20 (2007), 2539–2550.
30. 30 Maurer, M.S., Spevack, D., Burkhoff, D., Kronzon, I., Diastolic dysfunction: can it be diagnosed by Doppler echocardiography?. J Am Coll Cardiol 44:8 (2004), 1543–1549.
31. 31 Tschope, C., Paulus, W.J., Is echocardiographic evaluation of diastolic function useful in determining clinical care? Doppler echocardiography yields dubious estimates of left ventricular diastolic pressures. Circulation 120:9 (2009), 810–820 discussion 820.
32. 32 Wang, J., Khoury, D.S., Thohan, V., Torre-Amione, G., Nagueh, S.F., Global diastolic strain rate for the assessment of left ventricular relaxation and filling pressures. Circulation 115:11 (2007), 1376–1383.
33. 33 Tsai, C.T., Wu, C.K., Lee, J.K., et al. TNF-alpha down-regulates sarcoplasmic reticulum Ca(2)(+) ATPase expression and leads to left ventricular diastolic dysfunction through binding of NF-kappaB to promoter response element. Cardiovasc Res 105:3 (2015), 318–329.
34. 34 Ridker, P.M., Cannon, C.P., Morrow, D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352:1 (2005), 20–28.
35. 35 Ridker, P.M., Morrow, D.A., Rose, L.M., Rifai, N., Cannon, C.P., Braunwald, E., Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 45:10 (2005), 1644–1648.
36. 36 Lee, J.K., Lin, H.H., Tsai, C.T., et al. Differential association of proinflammatory cytokines with left ventricular diastolic dysfunction in subjects with and without continuous ambulatory peritoneal dialysis. Nutr Metab Cardiovasc Dis 22 (2012), 974–980.